Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Non-Current Assets: 2011-2024

Historic Non-Current Assets for Niagen Bioscience (NAGE) over the last 11 years, with Dec 2024 value amounting to $4.2 million.

  • Niagen Bioscience's Non-Current Assets rose 3.08% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.5 million, marking a year-over-year increase of 3.08%. This contributed to the annual value of $4.2 million for FY2024, which is 23.09% down from last year.
  • As of FY2024, Niagen Bioscience's Non-Current Assets stood at $4.2 million, which was down 23.09% from $5.4 million recorded in FY2023.
  • Niagen Bioscience's Non-Current Assets' 5-year high stood at $8.9 million during FY2021, with a 5-year trough of $4.2 million in FY2024.
  • Its 3-year average for Non-Current Assets is $5.7 million, with a median of $5.4 million in 2023.
  • Per our database at Business Quant, Niagen Bioscience's Non-Current Assets surged by 45.54% in 2021 and then fell by 27.50% in 2023.
  • Niagen Bioscience's Non-Current Assets (Yearly) stood at $6.1 million in 2020, then surged by 45.54% to $8.9 million in 2021, then fell by 16.17% to $7.5 million in 2022, then dropped by 27.50% to $5.4 million in 2023, then declined by 23.09% to $4.2 million in 2024.